Negative controls of cell proliferation: human prostate cancer cells and androgens.
about
Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediatorSupervillin associates with androgen receptor and modulates its transcriptional activityHormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responsesSteroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferationBisphenol-A and the great divide: a review of controversies in the field of endocrine disruptionUnraveling insulin-like growth factor binding protein-3 actions in human diseaseThe F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapistsNon-monotonic dose-response relationships and endocrine disruptors: a qualitative method of assessmentEnvironmental endocrine disruptors: Effects on the human male reproductive systemEDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting ChemicalsEffect of small molecules modulating androgen receptor (SARMs) in human prostate cancer modelsThe E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutantsNon-monotonic dose responses in studies of endocrine disrupting chemicals: bisphenol a as a case studyBipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.Key regulators in prostate cancer identified by co-expression module analysisPerinatal exposure to environmentally relevant levels of bisphenol A decreases fertility and fecundity in CD-1 miceMale reproductive cancers and infertility: a mutual relationship.Effect of serum testosterone and percent tumor volume on extra-prostatic extension and biochemical recurrence after laparoscopic radical prostatectomyCovalent modification of proteins by ligands of steroid hormone receptorsSex Hormone Binding Globulin Modifies Testosterone Action and Metabolism in Prostate Cancer CellsRegulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology.APRIN is a unique Pds5 paralog with features of a chromatin regulator in hormonal differentiation.Colloidal drug formulations can explain "bell-shaped" concentration-response curves.Androgen receptor coactivators that inhibit prostate cancer growthThe activation of OR51E1 causes growth suppression of human prostate cancer cells.Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.Minireview: Endocrine Disruptors: Past Lessons and Future Directions.Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro.Caspase-2-Based Regulation of the Androgen Receptor and Cell Cycle in the Prostate Cancer Cell Line LNCaPAndrogen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP.Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone.Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replaSupraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer.
P2860
Q24290153-B8A8E6C7-DE6F-4768-802F-E0F968893F16Q24530343-F394B352-6247-4AE9-8806-C9F713CC01E6Q24613799-97270BCA-021F-4467-988A-C73F694C8436Q24631073-17A6EAD7-7077-4FB6-BCC6-D4F1530B8AA6Q24648358-F3B91B4A-94E1-47D3-881D-C5D123F00D42Q24650060-D9D642FF-1561-46CF-9615-2FA036D156C2Q24800464-711E5292-CD1C-4A3F-8A6C-AF5E514FDF32Q26773738-42EDB868-B8CD-49F3-BB25-1F815BAE2185Q27025497-29DE1859-85C5-4429-920A-4B7B125B73EEQ28070418-8186848D-CC03-403B-8469-255654F90B6FQ28383132-F5FA88E2-680B-453E-AAE9-CD1BFC2CEEEFQ28487784-21899F16-316B-49BC-AB5E-08604C369331Q29617764-7F5E1F62-D935-4F97-AFA1-D7E70B74B5F4Q33676877-497F0331-0357-4929-AFBD-5E870FC32EC7Q34124650-18CB5333-D549-4D65-8C5A-FB0A40C3AE98Q34227242-DF00C51A-B96E-49FC-BD78-9EB31AB6D59CQ34645685-366EE7B3-764C-499A-8EF0-399F5D7802F1Q34834773-218367BE-8FE2-4258-AEB4-133BBE81D5C6Q35585478-A90C19B2-247F-4884-8091-D2D69E839252Q36530243-D4641EB5-8BD8-4297-BAD3-628A26D21052Q37298263-63CD2B86-0D44-48AE-9808-CD8139033CC8Q37470847-B9B2553E-01CA-4D83-AF98-736EBBB12AF8Q37515730-A4038417-D2D2-46D4-9DEF-FAA5DAC83427Q37664867-181884F3-26A8-49BE-A1F2-25C2D717EABBQ37701412-A74275F0-84BF-47FB-B4A4-9FFCC77A70D1Q38265571-2C77E8AB-ED7D-49F8-9F98-6718257DDE64Q38760187-C15785F8-479E-4702-BD9F-4FD7FA723C56Q38784791-A3F52A75-1C30-459D-8B7C-F4EB70EDB9FAQ38835887-2B996F3D-7661-4771-B5D5-F0EB6BFBA635Q38985492-1703C22B-2B41-4A7F-B045-0C9663CF371BQ39172228-6BAAC85D-EE68-4BB0-986D-2D82B9ABA089Q40399537-5B0325A5-B403-4928-8DD6-C8003343FB27Q41637744-CAF2CAE2-AA86-4372-B09C-EA17A6EA9513Q41677569-1F87422F-C231-42C4-9BCC-4B895B675466Q49631417-3422D276-1D49-4D83-B3B7-059AB0DEB2B2Q55096243-383413FF-5836-46C6-9979-2CBA5FA07ACB
P2860
Negative controls of cell proliferation: human prostate cancer cells and androgens.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Negative controls of cell proliferation: human prostate cancer cells and androgens.
@en
type
label
Negative controls of cell proliferation: human prostate cancer cells and androgens.
@en
prefLabel
Negative controls of cell proliferation: human prostate cancer cells and androgens.
@en
P2093
P1433
P1476
Negative controls of cell proliferation: human prostate cancer cells and androgens.
@en
P2093
P304
P407
P577
1989-07-01T00:00:00Z